One of the hottest names in chronic care just got nine-figures hotter after Cadence hauled in $100M of Series C funding to scale up with AI agents.
Welcome to the unicorn club. The round vaulted Cadence’s valuation to $1.2B as it looks to extend the reach of its Clinical Intelligence platform to more patients managing chronic conditions like hypertension, diabetes, and heart failure.
- The platform is purpose-built to deliver continuous support between visits, with regular vital monitoring and AI agents that translate the data into timely medication adjustments and personalized lifestyle coaching.
- Cadence integrates directly with its partners’ EHRs and clinical workflows, then equips every patient with connected devices that allow its system – supervised by physicians – to flag high-risk patients and predict adverse events before they happen.
Cadence lets its numbers do the talking. It’s easy to see why.
- 70% relative improvement in blood pressure control (JACC).
- 27% fewer hospital admissions (Mayo Clinic Proceedings).
- 230% increase in heart failure patients on GDMT (JCF).
- $1,300 annual cost reduction per patient (Circulation).
Now it’s time to scale. Cadence is already treating 100k patients, and this investment will support the infrastructure “to treat millions.”
- The current partner roster includes over 20 major health systems, including new additions like Texas Health Resources and Duke Health, which liked working with Cadence so much that it participated in the round.
- The word on the street is annualized revenue is pacing $140M for FY 2026, more than double the $62M it brought in last year.
Last but not least. Scaling from thousands of patients to millions of patients is no small task, and Cadence is working on deploying new AI agents to help carry the load.
- A new prescription hypertension management agent is reportedly en route, which “pre-authorizes” medication recommendations to steer patients toward their blood pressure goals, with new prescriptions and dose changes made autonomously by the AI.
- That falls squarely in medical device territory, and Cadence is actively working with regulators to bring it to patients – including an application to the FDA’s TEMPO pilot that will let certain devices for chronic care on the market before they’re officially approved.
The Takeaway
Chronic disease is the single largest driver of healthcare spending in America, and a significant amount of that cost is avoidable. Cadence is building the tools to avoid it, and another $100M should only help the cause.
